Global Breast Cancer Diagnostics Market - 2023-2030

Overview

According to the World Health Organization, breast cancer is the most commonly diagnosed type of cancer globally. The number of registered diagnostic breast cancer cases ase count has been estimated to climb from about 2.3 million new diagnoses in 2020 and is expected to more than 3 million in 2040. Invasive ductal carcinoma is the most common type of breast cancer, which starts in the mammary glands and spreads to nearby tissue. For every 10 breast cancer cases, 7 to 8 are invasive ductal carcinoma.

Aging is one of the most prevalent causes of breast cancer in women. According to the American Cancer Society, in February 2022, 1 out of 8 women younger than 45 years, 2 out of 3 in 55 years or older.

Dynamics

Advancements in diagnostic technologies

Advancements in breast cancer screening provide better outcomes when compared to conventional mammography. Integrating Artificial intelligence and deep learning makes breast cancer screening more accurate and reliable. Integration of machine learning with diagnostic techniques lead to more accurate treatment outcomes in breast cancer patients.

For instance, in January 2022, Duke University researchers created an Artificial Intelligence (AI) platform to analyze potentially cancerous lesions in mammography scans and determine whether patients should receive invasive biopsies. This AI helped to detect suspicious lesions that could be used to train students on how to read mammography images and can help physicians make health care decisions. Furthermore, this AI technology could be used for making wise decisions.

Furthermore, in February 2023, FathomX Pte Ltd. launched mammography using AI and deep learning to conduct R&D for early breast cancer diagnosis. In mammography-based breast cancer screening, the company's proprietary AI technology makes it possible to detect signs of cancerous tissue on X-ray images more quickly and accurately.

Furthermore, the prevalence of breast cancer, the need for early diagnosis, and product approvals are a few factors that drive the market in the forthcoming period.

False positive results

False-positive results are more common in women who are younger, have dense breasts, have had breast biopsies, have breast cancer in the family, or are taking estrogen. About half of the women getting annual mammograms over a 10-year period will have a false-positive finding at some point. Past history reduces their odds of a false-positive finding by about half.

Segment Analysis

The global breast cancer diagnostics is segmented based on cancer type, test type, spread, stage, end user, and region.

Early detection is crucial in improving breast cancer treatment. Innovations in screening methods have played a pivotal role in detecting breast cancer at its earliest stages. Digital mammography and tomosynthesis have replaced traditional film mammography, providing more precise and detailed images. Unlike conventional mammography, digital mammography and contrast-enhanced mammography offer better diagnosis and, thus, better treatment.

For instance, in January 2023, Bayer's iodine-based contrast agent Ultravist-300, -370 received the green light for indication extension for contrast-enhanced mammography (CEM) in a European Workshare Procedure. CEM is an emerging modality combining digital mammography with the administration of a contrast agent. Strategically expands Bayer's portfolio in breast imaging, including contrast agents and injectors. These factors are likely to increase the mammography segment in the forecast period.

Geographical Analysis

North America dominated the breast cancer diagnostics market in 2022. It is estimated to hold the largest market size over the forecast period (2022-2029) owing to rising breast cancer cases and increasing technological advancements in cancer diagnosis. For instance, as per the statistics from Breastcancer.org, as of January 2022, over 3.8 million women with a history of breast cancer in the U.S., and about 1 in 8 U.S. women (about 13%) in their lifetime would develop invasive breast cancer.

In 2022, around 287,850 new cases of invasive breast cancer were diagnosed in U.S. women, also 51,400 new cases of non-invasive (in situ) breast cancer. In 2022 about 2,710 new cases of invasive breast cancer were detected in men. In 2022, over about 43,250 women in the U.S. died from breast cancer. In addition, increasing development by manufacturers in breast cancer diagnostics is driving the market growth in this region.

COVID-19 Impact Analysis

COVID-19 has negatively impacted the global market during the outbreak since, to prevent the COVID-19 infection, various restrictions and regulations were employed, making it difficult for people to perform mammography and other breast cancer diagnostic tests affecting the market. Furthermore, a retrospective study of cases diagnosed by a reference service in the public health system of Campinas, SP, Brazil, concluded that amid the COVID-19 pandemic, breast cancer diagnoses declined. Moreover, the cases detected indicated a worsened prognosis as early detection was not performed.

Many healthcare facilities postponed non-urgent procedures and screenings, which affected the number of women getting regular tests. Additionally, fears of contracting the virus in healthcare settings and mobility restrictions further reduced screening rates. Due to these above factors, the market has seen a decline rate during the pandemic period.

By Cancer Type

• Invasive lobular breast cancer
• Ductal carcinoma in situ (DCIS)
• Triple-negative breast cancer
• Inflammatory breast cancer
• Others

By Test Type

• Clinical Breast Exam

• Imaging Tests
  • Mammogram
  • MRI
  • Ultrasound
  • PET
  • Others

• Blood Tests

• Biopsies
  • Excisional biopsy
  • Incisional biopsy
  • Core biopsy
  • Fine-needle aspiration (FNA) biopsy
  • Others

• Others

By Spread

• Local
• Regional
• Distant

By Stage

• I
• II
• III
• IV

By End User

• Hospitals and Clinics
• Cancer Diagnostic Centers
• Cancer Research Institutes
• Medical Research Centers and Institutes
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Competitive Landscape

The major global players in the breast cancer diagnostics market include: Siemens Healthineers AG, Kheiron Medical Technologies, Bio-Rad Laboratories, Hologic, Inc., Quest Diagnostics Incorporated, FUJIFILM Holdings Corporation, GE Healthcare, Illumina, Inc., Metaltronica SpA, and Carestream Health among others.

Key Developments

• In May 2022, the U.S. Department of Health and Human Services (HHS), declared the availability of US$ 5 million for community health centers, funded by HHS's Health Resources and Services Administration, to increase equitable access to life-saving breast cancer screenings.
• In March 2022, Niramai received US FDA clearance for their first medical device, SMILE-100 System (breast thermography).

Why Purchase the Report?

• To visualize the global breast cancer diagnostics segmentation based on cancer type, test type, spread, stage, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of breast cancer diagnostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global breast cancer diagnostics market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies